Modern Biological Treatment Methods for Alopecia Areata: A Comprehensive Review

    January 2026 in “ International Journal of Innovative Technologies in Social Science ”
    Ilona Tadulewicz, Natalia Nowak, Mateusz Drozd … Zofia Gorzoch-Burduk
    Studysummary This review reports that ritlecitinib, baricitinib, and deuruxolitinib, all JAK inhibitors, are effective treatments for moderate-to-severe alopecia areata, with differences in selectivity and onset of action, and suggests that emerging biologic therapies may enhance treatment by offering more targeted immune modulation.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on rsglobal.pl →
    Discuss this study in the Community →

    Research cited in this study 41

    1. Efficacy and Safety of Deuruxolitinib, an Oral Selective Janus Kinase 1/2 Inhibitor, in Adults with Alopecia Areata: Results from the THRIVE-AA2 Phase 3, Randomized, Double-Blind, Controlled Trial Journal of the American Academy of Dermatology · 2025
    2. Alopecia Areata: A Comprehensive Review of Clinical, Immunologic, and Genetic Perspectives Discover Immunity. · 2025
    3. Evaluation of the Efficacy and Treatment-Emergent Adverse Events of Deuruxolitinib for Moderate to Severe Alopecia Areata: A Dose-Ranging Meta-Analysis of 1,372 Randomized Patients Frontiers in Medicine · 2025
    4. Effectiveness and Safety of Baricitinib in Severe Alopecia Areata: 48-Week Results Journal of the European Academy of Dermatology and Venereology · 2025
    5. Evaluating Current and Emerging JAK Inhibitors for Alopecia Areata: A Narrative Review Dermatology and Therapy · 2025
    6. Global Burden of Alopecia Areata from 1990 to 2019 and Emerging Treatment Trends Analyzed Through GBD 2019 and Bibliometric Data Scientific Reports · 2025
    7. Alopecia Areata: Pathogenesis, Diagnosis, And Therapies MedComm · 2025
    8. Safety and Efficacy of Ritlecitinib for the Treatment of Patients with Alopecia Areata: A Systematic Review and Meta-Analysis of Controlled Trials Journal of Clinical Medicine · 2025
    9. Long-Term Safety and Efficacy of Ritlecitinib in Adults and Adolescents with Alopecia Areata and at Least 25% Scalp Hair Loss: Results from the ALLEGRO-LT Phase 3, Open-Label Study Journal of the European Academy of Dermatology and Venereology · 2025
    10. Dupilumab and Alopecia Areata: A Possible Combined or Disturbance Therapy? A Review of the Literature Dermatology Practical & Conceptual · 2024
    11. Efficacy and Safety of Deuruxolitinib, an Oral Selective Janus Kinase Inhibitor, in Adults with Alopecia Areata: Results from the Phase 3 Randomized, Controlled Trial (THRIVE-AA1) Journal of the American Academy of Dermatology · 2024
    12. The Causal Relationship Between Gut Microbiota and Alopecia Areata: A Mendelian Randomization Analysis Frontiers in Microbiology · 2024
    13. Deciphering the Complex Immunopathogenesis of Alopecia Areata International Journal of Molecular Sciences · 2024
    14. Genetic Links Between Atopy, Allergy, and Alopecia Areata: Insights From a Mendelian Randomization Study Allergy Asthma and Clinical Immunology · 2024
    15. Exploring the Gut Microbiome and Metabolome in Individuals with Alopecia Areata Nutrients · 2024
    16. The Hormonal Background of Hair Loss in Non-Scarring Alopecias Biomedicines · 2024
    17. Long-Term Efficacy and Safety of Baricitinib in Patients With Severe Alopecia Areata: 104-Week Results From BRAVE-AA1 and BRAVE-AA2 Journal of the European Academy of Dermatology and Venereology · 2024
    18. Alopecia Areata: Current Treatments and New Directions American Journal of Clinical Dermatology · 2023
    19. Ritlecitinib: First Approval Drugs · 2023
    20. Clinical and Genetic Aspects of Alopecia Areata: A Cutting Edge Review Genes · 2023
    21. Oxidative Stress and Alopecia Areata Frontiers in medicine · 2023
    22. Efficacy and Safety of Ritlecitinib in Adults and Adolescents With Alopecia Areata: A Randomised, Double-Blind, Multicentre, Phase 2b–3 Trial The Lancet · 2023
    23. Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata Over 52 Weeks in Phase III Trials American Journal of Clinical Dermatology · 2023
    24. The Burden of Alopecia Areata: A Scoping Review Focusing on Quality of Life, Mental Health, and Work Productivity Journal of the European Academy of Dermatology and Venereology · 2023
    25. Anxiety, Depression, and Quality of Life in Children and Adults With Alopecia Areata: A Systematic Review and Meta-Analysis Frontiers in Medicine · 2022
    26. An Overview of JAK/STAT Pathways and JAK Inhibition in Alopecia Areata Frontiers in immunology · 2022
    27. A Potential Predictive Role of the Scalp Microbiome Profiling in Patients with Alopecia Areata: Staphylococcus Caprae, Corynebacterium, and Cutibacterium Species Microorganisms · 2022
    28. Gut Microbiota in Alopecia Areata Advances in Dermatology and Allergology · 2022
    29. Immunology of Alopecia Areata Central-European Journal of Immunology/Central European Journal of Immunology · 2020
    30. Hair Follicle Immune Privilege and Its Collapse in Alopecia Areata Experimental dermatology · 2020
    31. The Role of Janus Kinase Inhibitors in the Treatment of Alopecia Areata: A Systematic Review Dermatologic therapy · 2019
    32. Response to Ustekinumab in Three Pediatric Patients with Alopecia Areata Pediatric dermatology · 2018
    33. Alopecia Areata: A Review of Disease Pathogenesis British journal of dermatology/British journal of dermatology, Supplement · 2018
    34. Association of Alopecia Areata with Atopic Dermatitis and Chronic Spontaneous Urticaria Allergy and asthma proceedings · 2018
    35. JAK Inhibitors in Dermatology: The Promise of a New Drug Class Journal of the American Academy of Dermatology · 2017
    36. Safety and Efficacy of the JAK Inhibitor Tofacitinib Citrate in Patients with Alopecia Areata JCI insight · 2016
    37. Investigation of Oxidative Stress in Patients with Alopecia Areata and Its Relationship with Disease Severity, Duration, Recurrence, and Pattern Clinical and experimental dermatology · 2014
    38. Alopecia Areata Is Driven by Cytotoxic T Lymphocytes and Is Reversed by JAK Inhibition Nature medicine · 2014
    39. Oxidative Stress in Alopecia Areata: A Case-Control Study American Journal of Clinical Dermatology · 2013
    40. Genome-Wide Association Study in Alopecia Areata Implicates Both Innate and Adaptive Immunity Nature · 2010
    41. Recurrence of Alopecia Areata in a Patient Receiving Etanercept Injections Archives of Dermatology · 2005